Havrix Za Odrasle (Hepatitis A Virus (Inactivated), Algeldrate)

Havrix Za Odrasle is indicated for the active immunization of adults against hepatitis A virus infection.

• Primary prevention of hepatitis A in individuals who have not been previously immunized.
• Protection for travelers to regions where hepatitis A is endemic.
• Use in outbreak settings to quickly establish herd immunity.
• Immunization of people with occupational exposure to hepatitis A (e.g., laboratory workers).
• Administration before planned long‑term travel or relocation to high‑risk areas.

The safety profile of Havrix Za Odrasle reflects the typical reactions observed with inactivated viral vaccines.

Common

• Mild pain, redness, or swelling at the injection site.
• Low‑grade fever or feeling of fatigue within 24‑48 hours.
• Headache or mild muscle aches.
• Transient nausea.
• Mild rash or itching at distant skin sites.

Serious

• Severe allergic reaction (anaphylaxis) characterized by difficulty breathing, swelling of the face or throat.
• High fever lasting more than 48 hours.
• Neurological symptoms such as Guillain‑Barré syndrome (rare).
• Persistent joint pain or swelling.
• Unexplained bleeding or bruising.

Before administering Havrix Za Odrasle, health professionals should review patient history and consider specific precautionary measures to ensure safe vaccination.

• Delay vaccination in individuals with a known severe allergy to any vaccine component, including algeldrate.
• Postpone the dose if the person has an acute moderate or severe illness with fever.
• Use caution in patients with weakened immune systems; vaccine may be less effective.
• Discuss the benefits and risks with pregnant or breastfeeding women, as safety data are limited.
• Verify that the vaccine has been stored and handled according to the manufacturer’s temperature requirements.
• Avoid intramuscular injection into areas with existing skin infections.

Havrix Za Odrasle does not have many documented drug interactions, but certain concomitant therapies may influence its immunogenicity or safety.

Avoid

• Concurrent administration of other live vaccines (e.g., measles, mumps, rubella) within four weeks.
• Use of immunoglobulin products or blood products within three months, which may reduce vaccine effectiveness.

Use with caution

• Systemic corticosteroids or other immunosuppressive agents; may diminish antibody response.
• Antipyretic or analgesic medications taken prophylactically; generally acceptable but monitor for reduced reactogenicity.
• Ongoing chemotherapy or biologic therapy; consider timing of vaccination relative to treatment cycles.